NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis → America could fall from this event (From Porter & Company) (Ad) Free FLGT Stock Alerts $22.21 +0.02 (+0.09%) (As of 01:28 PM ET) Add Compare Share Share Today's Range$22.21▼$22.9150-Day Range$20.03▼$23.7452-Week Range$19.88▼$44.09Volume59,318 shsAverage Volume197,618 shsMarket Capitalization$664.52 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Fulgent Genetics alerts: Email Address Fulgent Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside35.1% Upside$30.00 Price TargetShort InterestHealthy3.48% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.04) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.34 out of 5 starsMedical Sector405th out of 2,771 stocksMedical Laboratories Industry19th out of 57 stocks 3.0 Analyst's Opinion Consensus RatingFulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageFulgent Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.48% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 9.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fulgent Genetics is -0.67. Previous Next 3.0 News and Social Media Coverage News SentimentFulgent Genetics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Fulgent Genetics this week, compared to 1 article on an average week.Search Interest11 people have searched for FLGT on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows5 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders32.66% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fulgent Genetics are expected to grow in the coming year, from ($2.04) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fulgent Genetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. About Fulgent Genetics Stock (NASDAQ:FLGT)Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Read More FLGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FLGT Stock News HeadlinesMay 6, 2024 | finance.yahoo.comFulgent Genetics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 5, 2024 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Shares Gap Down to $21.24May 4, 2024 | finance.yahoo.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call TranscriptMay 4, 2024 | finance.yahoo.comFulgent Genetics Inc (FLGT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...May 4, 2024 | finance.yahoo.comQ1 2024 Fulgent Genetics Inc Earnings CallMay 3, 2024 | investorplace.comFLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024May 3, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, May 03, 2024May 3, 2024 | msn.comFulgent Genetics reports mixed Q1 results; reaffirms FY24 outlookMay 3, 2024 | finance.yahoo.comFulgent Genetics Inc (FLGT) Q1 2024 Earnings: Misses Analyst Forecasts with Wider LossesMay 3, 2024 | businesswire.comFulgent Reports First Quarter 2024 Financial ResultsMay 2, 2024 | markets.businessinsider.comFulgent Genetics is about to announce earnings — here's what Wall Street expectsApril 17, 2024 | morningstar.comFulgent Genetics Inc FLGTApril 11, 2024 | businesswire.comFulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024April 11, 2024 | finance.yahoo.comFulgent Genetics (NASDAQ:FLGT) shareholders have earned a 26% CAGR over the last five yearsMarch 16, 2024 | finance.yahoo.comFLGT Apr 2024 20.000 callMarch 1, 2024 | seekingalpha.comFulgent Genetics (FLGT) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comFulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2024 | finance.yahoo.comAn Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% UndervaluedFebruary 29, 2024 | insidermonkey.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 Fulgent Genetics Inc Earnings CallFebruary 28, 2024 | markets.businessinsider.comHere's what to expect from Fulgent Genetics's earnings reportFebruary 28, 2024 | finance.yahoo.comFulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023February 28, 2024 | businesswire.comFulgent Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | seekingalpha.comFulgent Genetics: Buy Growth Ahead Below Liquidation ValueFebruary 17, 2024 | finance.yahoo.comFLGT Mar 2024 30.000 callSee More Headlines Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/14/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:FLGT CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,184Year Founded2011Price Target and Rating Average Stock Price Target$30.00 High Stock Price Target$35.00 Low Stock Price Target$25.00 Potential Upside/Downside+35.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,820,000.00 Net Margins-57.72% Pretax Margin-58.15% Return on Equity-2.92% Return on Assets-2.70% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual Sales$289.21 million Price / Sales2.30 Cash Flow$3.31 per share Price / Cash Flow6.70 Book Value$38.24 per share Price / Book0.58Miscellaneous Outstanding Shares29,920,000Free Float20,151,000Market Cap$663.92 million OptionableOptionable Beta1.43 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Ming Hsieh (Age 68)Chairman & CEO Comp: $2.31MMr. Jian Xie (Age 58)COO & President Comp: $868.74kMr. Paul Kim (Age 57)Chief Financial Officer Comp: $879.61kDr. Hanlin Gao D.A.B.M.G. (Age 57)FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director Comp: $720.7kMs. Natalie PrescottGeneral Counsel & Chief Privacy OfficerMs. Doreen NgVP of Operations & Compliance and GM of Houston OfficeMr. Jakub SramVice President of Business Development & SalesMs. Ellen TsuiVice President of Human ResourcesMr. Brandon PerthuisChief Commercial OfficerDr. Lawrence M. Weiss M.D. (Age 67)Chief Medical Officer More ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLCareDxNASDAQ:CDNACelcuityNASDAQ:CELCViridian TherapeuticsNASDAQ:VRDNSera PrognosticsNASDAQ:SERAView All CompetitorsInsiders & InstitutionsCANADA LIFE ASSURANCE CoBought 2,879 shares on 5/14/2024Ownership: 0.097%Vanguard Group Inc.Bought 8,257 shares on 5/10/2024Ownership: 4.760%Acadian Asset Management LLCBought 9,044 shares on 5/10/2024Ownership: 0.030%State Board of Administration of Florida Retirement SystemBought 8,209 shares on 5/9/2024Ownership: 0.027%Russell Investments Group Ltd.Sold 9,308 shares on 5/8/2024Ownership: 0.133%View All Insider TransactionsView All Institutional Transactions FLGT Stock Analysis - Frequently Asked Questions Should I buy or sell Fulgent Genetics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FLGT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares. View FLGT analyst ratings or view top-rated stocks. What is Fulgent Genetics' stock price target for 2024? 2 brokerages have issued twelve-month target prices for Fulgent Genetics' shares. Their FLGT share price targets range from $25.00 to $35.00. On average, they predict the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 35.1% from the stock's current price. View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts. How have FLGT shares performed in 2024? Fulgent Genetics' stock was trading at $28.91 at the start of the year. Since then, FLGT shares have decreased by 23.2% and is now trading at $22.21. View the best growth stocks for 2024 here. When is Fulgent Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 2nd 2024. View our FLGT earnings forecast. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.61. The firm had revenue of $70.51 million for the quarter, compared to the consensus estimate of $67.14 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 2.92% and a negative net margin of 57.72%. What ETFs hold Fulgent Genetics' stock? ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Amplify Treatments, Testing and Advancements ETF (GERM).Global X Genomics & Biotechnology ETF (GNOM). What guidance has Fulgent Genetics issued on next quarter's earnings? Fulgent Genetics issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of -1.050--1.050 for the period, compared to the consensus estimate of -1.060. The company issued revenue guidance of $280.0 million-$280.0 million, compared to the consensus revenue estimate of $279.4 million. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT). When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Fulgent Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.76%), Empowered Funds LLC (0.37%), Principal Financial Group Inc. (0.35%), Mirae Asset Global Investments Co. Ltd. (0.29%), Russell Investments Group Ltd. (0.13%) and CANADA LIFE ASSURANCE Co (0.10%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Fulgent Genetics have any subsidiaries? The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.Read More This page (NASDAQ:FLGT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.